RELATIVITY-047, a global, randomized, double-blind Phase 2/3 study of patients with metastatic or unresectable melanoma in the first-line setting, recently demonstrated the clinical success of an anti-LAG3/PD-1 combination therapy and led to the FDA approving relatlimab with nivolumab. The gene discussed is PDCD1; the disease is melanoma.